Navigation Links
BioMarin Announces Third Quarter 2010 Financial Results
Date:10/28/2010

er revenue for the period.Reversal of Tax Valuation AllowanceDuring the third quarter of 2010, the company recorded a non-cash gain in its consolidated statement of operations totaling $223.1 million.  Based upon the company's expectations of generating U.S. taxable income in the future and the resulting expected utilization of its net operating loss carryforwards and R&D tax credits, the company has recorded the $223.1 million non-cash benefit to the Provision for (benefit from) income taxes line item on the consolidated statement of operations and a corresponding increase in other current assets and other assets categories on our balance sheet.

Other Transactions During Q3 2010During the third quarter of 2010, the company acquired ZyStor Therapeutics, Inc. and incurred one-time costs associated with closing the transaction totaling $1.8 million, which are classified as general and administrative expenses.  

In addition, the company recorded intangible asset amortization and contingent consideration costs during the third quarter of $4.0 million.  The increase in such costs compared with prior quarters is due to the recognition of additional contingent consideration expense associated with the increased likelihood of achieving certain near term milestones related primarily to BMN-673 development including the filing of an IND and clinical milestones.

2010 Guidance Revenue Guidance ($ in millions)Item

2010 Guidance

Previous 2010 GuidanceTotal BioMarin Revenues

$372 to $393

$370 to $393Total Net Product Revenues

$367 to $387

$365 to $387Naglazyme Net Product Revenue

$194 to $200

$190 to $200Kuvan Net Product Revenue

Unchanged

$98 to $102Aldurazyme Net Product Revenue to BioMarin

$68 to $75

$70 to $75Firdapse Net Product Revenue

Unchanged

$7 to $10Selected Income Statement Guidance ($ in millions)Item

2010 Guidance


'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. BioMarin to Host a Research and Development Day on October 19th
2. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
3. BioMarin to Present at the UBS Global Life Sciences Conference
4. BioMarin to Present at the Stifel Nicolaus Healthcare Conference
5. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
6. BioMarin Acquires ZyStor Therapeutics, Inc.
7. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
8. BioMarin to Acquire LEAD Therapeutics
9. BioMarin to Present at the Credit Suisse Healthcare Conference
10. BioMarin Announces Third Quarter 2009 Financial Results
11. BioMarin to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DUBLIN , Jan. 15, 2014  Research and Markets ... "Dental Consumables Market - Global Industry Analysis, Size, ... report to their offering. (Logo: ... products which are used on patients in order to ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... DIEGO, Aug. 12, 2011 / PRNewswire/ -- Halozyme ... company developing and commercializing products targeting the extracellular ... at the Wedbush 2011 Life Sciences Conference in New ... at 9:10 a.m. EDT (6:10 a.m. PDT). To listen ...
... WOODLANDS, Texas, Aug. 11, 2011 Lexicon Pharmaceuticals, ... company focused on discovering breakthrough treatments for human disease, ... , Lexicon,s president and chief executive officer, will present ... on Tuesday, August 16, 2011 at 1:15 p.m. Eastern ...
Cached Medicine Technology:Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17 2Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference 2
(Date:7/9/2014)... active in almost all types of cancer sends the ... help fuel a tumour,s uncontrolled growth, new research suggests. ... identified a molecular trigger responsible for ratcheting up activity ... that makes the building blocks cancer cells need to ... pathway, called SREBP, controls the flow of messages to ...
(Date:7/9/2014)... cancer, researchers have uncovered mutations in a cell-signaling pathway ... knowledge may expand treatments for patients because drugs targeting ... are in clinical trials. , Reporting July 9 in ... (TCGA), including researchers at Washington University School of Medicine ... studied tumors from 230 patients with lung adenocarcinoma. , ...
(Date:7/9/2014)... New findings from Fox Chase Cancer Center paint a ... subset of breast cancers that have spread to the ... Tumors that grow into the skin, regardless of size ... classified as stage III and called "locally advanced" ... of cancer, often with poor survival. Locally advanced breast ...
(Date:7/9/2014)... injection drug users in Russia might contribute to ... study, conducted by researchers from Boston University Schools ... St. Petersburg Pavlov State University, sought to discover ... outcomes of a cohort of HIV-positive people with ... were arrested by police were more likely to ...
(Date:7/9/2014)... are personal and subjective, the human brain turns ... emotions across different senses, situations and even people, ... Adam Anderson. , "We discovered that fine-grained patterns ... area of the brain associated with emotional processing, ... individual,s subjective feeling," says Anderson, associate professor of ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Study cracks how the brain processes emotions 2
... remains unknown. Scientists believe people may have gotten the virus from ... want to quarantine the pets as well as the people," suggested ... of Texas Medical Branch in Galveston. "If it's been shown that ... much of a leap of faith that it will transmit to ...
... viral cold are common in preschoolers. These attacks are ... school age. //The current recommendation is that parents administer ... But whether or not the steroids are effective is ... steroids was no more effective than placebo in reducing ...
... cardiac death is termed sudden arrhythmic death syndrome or ... United States.// Most of these sudden deaths involve middle-aged ... in young people are rare, experts say they do ... the families. ,Previous research indicates about 4 ...
... with type 2 diabetes and now research shows this diagnosis ... heart attack and stroke. //Specifically, the research shows younger adults ... suffer a heart attack and 30-times more likely to suffer ... that huge numbers of people are going to get heart ...
... An oral drug given after a standard six-month treatment ... to new research.// ,Venous thromboembolism (VTE) affects approximately ... thrombosis (blood clots common in the thigh and back) ... Despite progress in diagnosis and treatment, VTE is still ...
... may soon be fighting a losing battle. Scientists from ... stopped the tuberculosis pathogen's ability to operate from the ... system in a cell called a macrophage. ,The ... triggered by a host protein called interferon-gamma that disarms ...
Cached Medicine News:Health News:Some pets found to be SARS carriers 2Health News:Extended Therapy for Blood Clots 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: